ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALDX vs IBO // RSI-14 & 200D SMA MOMENTUM

Aldeyra Therapeutics Inc. (NASDAQ) VS. Impact BioMedical Inc. (NYSE) • 15-METRIC TALLY: ALDX 2 — IBO 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: IBO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALDX VS. IBO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALDX IBO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — -30.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -27.50% -7.50 IBO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -5.72% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.88 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ALDX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 32.6 47.2 -14.60 IBO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $35.2M $34.3M $922.2K ALDX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALDX REV IBO REV ALDX GROSS % IBO GROSS % ALDX FCF IBO FCF
FY 2025 $98.7M $32.0K — -50.0% -$33.3M -$1.9M
FY 2024 $168.3M $80.5M — — -$43.2M -$2.9M
FY 2023 $119.8M $11.3M — — -$30.3M -$2.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALDX // BETA —
IBO // BETA —